Sustainability & Climate

As Harmony Biosciences presents at JPM, investors will scrutinize its strategy for sustaining growth beyond its star drug and advancing its rare disease pipeline.

The deal creates an end-to-end commercialization powerhouse, tackling pharma's toughest payer, reimbursement, and patient affordability challenges.

With $16.4M in new funding, STRM.BIO is advancing a novel gene therapy platform that uses natural vesicles to target bone marrow, offering new hope for rare diseases.

A new partnership brings a complex wealth-building insurance product to the digital age, offering instant decisions and no medical exams. Is this the future?

A new tri-specific antibody, IM1240, safely hits cancer cells at massive doses in preclinical studies, potentially solving a key toxicity problem in immunotherapy.

With a massive $200M Series C, Soley Therapeutics is using its AI cell-sensing platform to fast-track novel cancer drugs from code to clinic.

A new Deloitte study shows EV interest stalling as affordability woes and practical concerns push buyers back to gas and hybrids, rocking brand loyalty.

New IoT solution from Clarios prevents costly trailer failures and protects cold chain goods by providing real-time battery health insights.

The newly formed food tech giant will outline its strategic priorities, with investors closely watching for synergy updates and future growth plans.

Anterix hires a new product chief and sees its COO depart, signaling a major pivot from spectrum provider to a full-service solutions leader for utilities.

The Japanese government's 'SUI COLLECTION' is showcasing hidden artisanal treasures to the world, blending tradition with modern luxury in a bold cultural push.

Closing 2025 with two major acquisitions, The Milestone Group signals a larger investor trend: a strategic rush into the booming Mountain West.

Aerospace veteran John Slattery brings his expertise to Orbis International, aiming to elevate the mission of its unique Flying Eye Hospital.

With star hires and proprietary data analytics, Abacus Global Management is making an ambitious play for the booming asset-based finance sector.

With its first drug approved and a deep pipeline, all eyes are on Nuvation Bio's CEO David Hung at the upcoming J.P. Morgan Healthcare Conference.

UBC's strategic acquisition of Evidinno creates a new powerhouse in biopharma evidence, combining global scale with AI-driven health economic insights.

A landmark trial reveals a new drug combination from BeOne Medicines extends life significantly in advanced stomach cancer, poised to become the new standard.

For the fourth straight year, HRL Labs is a top workplace. Discover how its unique R&D culture and strategic vision set it apart in a competitive market.

A new nationwide study reveals a massive gap in care for heart failure patients, costing lives and billions. Why are proven, cheap medications being overlooked?

A prominent healthcare executive is using his personal resources to empower students to develop actionable solutions for combating intolerance and hate.